A Phase 4 interventional study of Brentuximab Vedotin in Hodgkin Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 34th largest by enrollment, is one of 7 that started in 2014, is one of 2 in phase 4, and was the 27th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
15 studies in Hodgkin Disease by Takeda: 3 open now, 4 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 15 studies in Hodgkin Disease by Takeda, this one is the only one that started in 2014, is one of 2 in phase 4, and was the 6th registered.
Takeda’s Hodgkin Disease studies by the year they started, since 1997.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Takeda’s 15 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have relapsed or refractory Hodgkin Lymphoma. This study will look at the overall response of people who took brentuximab vedotin.
The study will enroll 60 patients. Participants received:
This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 6 to 7 years. Participants will make multiple visits to the clinic, and will be contacted by telephone every 3 months for 18 months after the end of treatment (EOT) for follow-up assessment of overall survival and then every 6 months until death, study closure, or 5 years after enrollment of the last participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:
Exclusion Criteria:
Participants who meet any of the following exclusion criteria are not to be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
Drug: Brentuximab Vedotin
Brentuximab vedotin IV infusion
Also known as: SGN-35, ADCETRIS
Objective Response Rate (ORR)
Objective response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
Time frame: Baseline until disease progression, death or end of study (EOS) (Up to 24 months)
Duration of Response (DOR)
DOR is defined as the time in months from the date of first documentation of a CR or PR response to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
Time frame: From first documented complete or partial remission until disease progression (Up to 24 months)
Progression Free Survival (PFS)
PFS is defined as time in months from start of study treatment to first documentation of objective tumor progression per IRF assessment or up to death due to any cause, whichever occurs first.
Time frame: Baseline until disease progression, death or end of treatment (EOT), and then every 3 months up to approximately 6 years
Complete Remission Rate
Complete remission rate is defined as percentage of participants with CR per IRF response assessment based on IWG criteria are reported. CR is defined as the disappearance of all evidence of disease.
Time frame: Baseline until disease progression, death or EOS (Up to approximately 6 years)
Duration of Complete Remission
Duration of CR is defined as the time from the date of first documentation of a CR or to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
Time frame: From first documented complete remission until disease progression (up to approximately 6 years)
Overall Survival (OS)
OS is the time in months from start of study treatment to date of death due to any cause.
Time frame: Every 3 months for 18 months after EOT, thereafter, every 6 months until the sooner of death, study closure, or 5 years after enrollment of the last participant (up to approximately 6 years)
Percentage of Participants Who Received Hematopoietic SCT
Time frame: Baseline up to EOS (up to approximately 6 years)
Number of Participants With Adverse Events (AEs), Drug-Related AEs, Grade 3 or Higher AEs, Serious Adverse Events (SAEs), Drug-Related SAEs and Grade 3 or Higher SAEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE a serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. AEs Grade 3 and higher are severe.
Time frame: From first dose through 30 days after the last dose of study medication (Up to 24 months)
Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs
Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
Time frame: From the first dose through 30 days after the last dose of study medication (Up to 24 months)
Antibody-drug Conjugate (ADC) Serum Concentrations
Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.
Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Serum Concentration of Total Antibodies (Conjugated and Unconjugated)
Blood samples were collected and tested for conjugated and unconjugated antibodies.
Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Monomethyl Auristatin E (MMAE) Serum Concentrations
Blood samples were collected and tested for MMAE serum concentrations.
Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Number of Participants With Antitherapeutic Antibodies (ATA)
Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-Baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-Baseline confirmed ATA positive responses) and neutralizing ATA (nATA) status. The confirmed ATA-positive samples were assessed for ATA titer and delineated into having high or low titers.
Time frame: Day 1 of every 3-week cycle up to 16 cycles and EOT (Up to 24 months)
Participants took part in the study at 18 investigative sites in Czech Republic, Germany, Malaysia, Poland, Spain, Thailand and Turkey, from 14 March 2014 to 12 March 2020.
| Milestone | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Started | 60 |
| Completed | 25 |
| Not completed | 35 |
| Withdrew: Death | 22 |
| Withdrew: Progressive disease | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal of informed consent | 2 |
| Withdrew: Symptomatic deterioration | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Reason not specified | 2 |
| Withdrew: Lost to follow-up | 1 |
Objective response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Objective Response Rate (ORR) | 50 (37 to 63) |
DOR is defined as the time in months from the date of first documentation of a CR or PR response to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Duration of Response (DOR) | 4.6 (3.42 to 7.85) |
PFS is defined as time in months from start of study treatment to first documentation of objective tumor progression per IRF assessment or up to death due to any cause, whichever occurs first.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Progression Free Survival (PFS) | 4.8 (2.96 to 5.32) |
Complete remission rate is defined as percentage of participants with CR per IRF response assessment based on IWG criteria are reported. CR is defined as the disappearance of all evidence of disease.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Complete Remission Rate | 13 (6 to 25) |
Duration of CR is defined as the time from the date of first documentation of a CR or to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Duration of Complete Remission | 6.1 (2.10 to NA) |
OS is the time in months from start of study treatment to date of death due to any cause.
| months | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Percentage of Participants Who Received Hematopoietic SCT | 53 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE a serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. AEs Grade 3 and higher are severe.
| Participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Any AEs | 52 |
| Grade 3 or higher AEs | 21 |
| Drug-related AEs | 41 |
| Drug-related Grade 3 or higher AEs | 11 |
| SAEs | 11 |
| Drug-related SAEs | 3 |
Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
| Participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Neutrophil count decreased | 2 |
| Lymphocyte count decreased | 1 |
| Alanine aminotransferase increased | 2 |
| Aspartate aminotransferase increased | 2 |
| Gamma-glutamyltransferase increased | 1 |
| Blood thyroid stimulating hormone increased | 1 |
| Platelet count decreased | 1 |
| Haemoglobin decreased | 1 |
| Blood alkaline phosphatase increased | 1 |
| Blood lactate dehydrogenase increased | 1 |
Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.
| ng/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 Day 1, Pre-Dose | 0.00 ± 0.000 |
| Cycle 1 Day 1, 10 minutes Post-Dose | 35504.65 ± 10226.104 |
| Cycle 1 Day 2, 24 hours Post-Dose | 14517.67 ± 4481.312 |
| Cycle 1 Day 15, 336 hours Post-Dose | 1410.43 ± 1946.525 |
| Cycle 2 Day 1, Pre-Dose | 526.42 ± 350.467 |
| Cycle 2 Day 1, 10 minutes Post-Dose | 37118.32 ± 11678.088 |
| Cycle 3 Day 1, Pre-Dose | 2283.30 ± 7552.322 |
| Cycle 3 Day 1, 10 minutes Post-Dose | 35878.77 ± 12724.898 |
| Cycle 3 Day 2, 24 hours Post-Dose | 14737.82 ± 4512.358 |
| Cycle 3 Day 15, 336 hours Post-Dose | 1586.45 ± 680.955 |
| Cycle 4 Day 1, Pre-Dose | 1313.56 ± 2566.360 |
| Cycle 4 Day 1, 10 minutes Post-Dose | 42915.34 ± 28221.764 |
| Cycle 5 Day 1, Pre-Dose | 1117.01 ± 637.637 |
| Cycle 5 Day 1, 10 minutes Post-Dose | 36418.77 ± 10041.935 |
| Cycle 6 Day 1, Pre-Dose | 1231.45 ± 714.383 |
| Cycle 6 Day 1, 10 minutes Post-Dose | 39000.95 ± 12484.458 |
| Cycle 7 Day 1, Pre-Dose | 1285.91 ± 712.625 |
| Cycle 7 Day 1, 10 minutes Post-Dose | 38814.82 ± 12471.299 |
| Cycle 8 Day 1, Pre-Dose | 1413.98 ± 782.391 |
| Cycle 8 Day 1, 10 minutes Post-Dose | 39027.22 ± 9919.251 |
| Cycle 9 Day 1, Pre-Dose | 1277.18 ± 594.603 |
| Cycle 9 Day 1, 10 minutes Post-Dose | 38359.15 ± 13421.064 |
| Cycle 10 Day 1, Pre-Dose | 1498.44 ± 754.721 |
| Cycle 10 Day 1, 10 minutes Post-Dose | 39890.12 ± 5376.038 |
| Cycle 11 Day 1, Pre-Dose | 1511.35 ± 461.907 |
| Cycle 11 Day 1, 10 minutes Post-Dose | 39132.17 ± 6316.541 |
| Cycle 12 Day 1, Pre-Dose | 1479.38 ± 397.816 |
| Cycle 12 Day 1, 10 minutes Post-Dose | 39955.13 ± 7821.656 |
| Cycle 13 Day 1, Pre-Dose | 1423.56 ± 415.744 |
| Cycle 13 Day 1, 10 minutes Post-Dose | 37609.69 ± 4563.601 |
| Cycle 14 Day 1, Pre-Dose | 1185.62 ± 422.664 |
| Cycle 14 Day 1, 10 minutes Post-Dose | 38282.29 ± 10324.023 |
| Cycle 15 Day 1, Pre-Dose | 2279.42 ± 2919.545 |
| Cycle 15 Day 1, 10 minutes Post-Dose | 39068.14 ± 7981.110 |
| Cycle 16 Day 1, Pre-Dose | 1452.23 ± 429.731 |
| Cycle 16 Day 1, 10 minutes Post-Dose | 38414.73 ± 9427.315 |
| End of Treatment | 1515.30 ± 6413.367 |
Blood samples were collected and tested for conjugated and unconjugated antibodies.
| ng/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 Day 1, Pre-Dose | 0.00 ± 0.000 |
| Cycle 1 Day 1, 10 minutes Post-Dose | 37329.59 ± 17724.247 |
| Cycle 1 Day 2, 24 hours Post-Dose | 23248.90 ± 8228.938 |
| Cycle 1 Day 15, 336 hours Post-Dose | 2791.49 ± 1413.452 |
| Cycle 2 Day 1, Pre-Dose | 1254.86 ± 774.586 |
| Cycle 2 Day 1, 10 minutes Post-Dose | 39801.87 ± 12914.837 |
| Cycle 3 Day 1, Pre-Dose | 2645.22 ± 5685.914 |
| Cycle 3 Day 1, 10 minutes Post-Dose | 36461.28 ± 11144.634 |
| Cycle 3 Day 2, 24 hours Post-Dose | 27071.46 ± 8069.489 |
| Cycle 3 Day 15, 336 hours Post-Dose | 4033.28 ± 1760.094 |
| Cycle 4 Day 1, Pre-Dose\ | 2600.73 ± 2275.881 |
| Cycle 4 Day 1, 10 minutes Post-Dose | 41823.31 ± 11761.223 |
| Cycle 5 Day 1, Pre-Dose | 2690.61 ± 1254.886 |
| Cycle 5 Day 1, 10 minutes Post-Dose | 43786.57 ± 15470.979 |
| Cycle 6 Day 1, Pre-Dose | 2806.17 ± 1021.877 |
| Cycle 6 Day 1, 10 minutes Post-Dose | 44936.89 ± 13827.929 |
| Cycle 7 Day 1, Pre-Dose | 3889.94 ± 6201.351 |
| Cycle 7 Day 1, 10 minutes Post-Dose | 41840.20 ± 12552.597 |
| Cycle 8 Day 1, Pre-Dose | 2932.19 ± 1089.138 |
| Cycle 8 Day 1, 10 minutes Post-Dose | 42013.77 ± 12754.334 |
| Cycle 9 Day 1, Pre-Dose | 2959.26 ± 970.811 |
| Cycle 9 Day 1, 10 minutes Post-Dose | 37300.95 ± 13442.910 |
| Cycle 10 Day 1, Pre-Dose | 3189.16 ± 1484.258 |
| Cycle 10 Day 1, 10 minutes Post-Dose | 38910.05 ± 6169.552 |
| Cycle 11 Day 1, Pre-Dose | 3393.07 ± 1160.604 |
| Cycle 11 Day 1, 10 minutes Post-Dose | 41238.25 ± 8081.750 |
| Cycle 12 Day 1, Pre-Dose | 3270.44 ± 965.895 |
| Cycle 12 Day 1, 10 minutes Post-Dose | 37550.64 ± 12459.906 |
| Cycle 13 Day 1, Pre-Dose | 3406.00 ± 1067.414 |
| Cycle 13 Day 1, 10 minutes Post-Dose | 35694.80 ± 3720.378 |
| Cycle 14 Day 1, Pre-Dose | 2723.01 ± 1286.457 |
| Cycle 14 Day 1, 10 minutes Post-Dose | 40848.64 ± 8704.538 |
| Cycle 15 Day 1, Pre-Dose | 3111.63 ± 941.200 |
| Cycle 15 Day 1, 10 minutes Post-Dose | 37091.56 ± 6644.258 |
| Cycle 16 Day 1, Pre-Dose | 3159.38 ± 1017.679 |
| Cycle 16 Day 1, 10 minutes Post-Dose | 39266.07 ± 9358.163 |
| End of Treatment | 2340.49 ± 6715.837 |
Blood samples were collected and tested for MMAE serum concentrations.
| pg/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 Day 1, Pre-Dose | 0.78 ± 5.976 |
| Cycle 1 Day 1, 10 minutes Post-Dose | 591.09 ± 662.608 |
| Cycle 1 Day 2, 24 hours Post-Dose | 6056.44 ± 3850.457 |
| Cycle 1 Day 15, 336 hours Post-Dose | 746.12 ± 1123.502 |
| Cycle 2 Day 1, Pre-Dose | 140.11 ± 111.036 |
| Cycle 2 Day 1, 10 minutes Post-Dose | 539.38 ± 593.150 |
| Cycle 3 Day 1, Pre-Dose | 130.62 ± 84.152 |
| Cycle 3 Day 1, 10 minutes Post-Dose | 484.88 ± 701.402 |
| Cycle 3 Day 2, 24 hours Post-Dose | 3076.75 ± 2330.510 |
| Cycle 3 Day 15, 336 hours Post-Dose | 442.63 ± 259.360 |
| Cycle 4 Day 1, Pre-Dose | 150.95 ± 123.841 |
| Cycle 4 Day 1, 10 minutes Post-Dose | 497.20 ± 520.110 |
| Cycle 5 Day 1, Pre-Dose | 153.95 ± 123.337 |
| Cycle 5 Day 1, 10 minutes Post-Dose | 392.50 ± 320.346 |
| Cycle 6 Day 1, Pre-Dose | 158.89 ± 109.024 |
| Cycle 6 Day 1, 10 minutes Post-Dose | 369.53 ± 260.871 |
| Cycle 7 Day 1, Pre-Dose | 185.91 ± 147.311 |
| Cycle 7 Day 1, 10 minutes Post-Dose | 363.83 ± 237.883 |
| Cycle 8 Day 1, Pre-Dose | 136.37 ± 86.947 |
| Cycle 8 Day 1, 10 minutes Post-Dose | 303.43 ± 202.351 |
| Cycle 9 Day 1, Pre-Dose | 142.30 ± 114.794 |
| Cycle 9 Day 1, 10 minutes Post-Dose | 224.52 ± 159.833 |
| Cycle 10 Day 1, Pre-Dose | 100.78 ± 57.270 |
| Cycle 10 Day 1, 10 minutes Post-Dose | 253.73 ± 113.311 |
| Cycle 11 Day 1, Pre-Dose | 158.09 ± 169.963 |
| Cycle 11 Day 1, 10 minutes Post-Dose | 302.60 ± 175.869 |
| Cycle 12 Day 1, Pre-Dose | 175.02 ± 141.192 |
| Cycle 12 Day 1, 10 minutes Post-Dose | 382.52 ± 428.255 |
| Cycle 13 Day 1, Pre-Dose | 146.76 ± 61.758 |
| Cycle 13 Day 1, 10 minutes Post-Dose | 258.78 ± 108.871 |
| Cycle 14 Day 1, Pre-Dose | 82.13 ± 22.661 |
| Cycle 14 Day 1, 10 minutes Post-Dose | 204.29 ± 121.162 |
| Cycle 15 Day 1, Pre-Dose | 133.78 ± 59.213 |
| Cycle 15 Day 1, 10 minutes Post-Dose | 246.63 ± 98.399 |
| Cycle 16 Day 1, Pre-Dose | 163.39 ± 114.821 |
| Cycle 16 Day 1, 10 minutes Post-Dose | 264.63 ± 103.269 |
| End of Treatment | 139.72 ± 220.211 |
Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-Baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-Baseline confirmed ATA positive responses) and neutralizing ATA (nATA) status. The confirmed ATA-positive samples were assessed for ATA titer and delineated into having high or low titers.
| Participants | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| ATA Positive | 21 |
| Transient Positive | 17 |
| Persistently Positive | 4 |
| ATA Titer Low (≤25) | 21 |
| ATA Titer High (>25) | 0 |
Collected over First dose of study drug up to 30 days post last dose of study drug (Up to 24 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin 1.8 mg/kg | 22/60 (36.7%) | 11/60 (18.3%) | 51/60 (85%) |
| Event | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| BronchitisInfections and infestations | 1/60 |
| PneumoniaInfections and infestations | 1/60 |
| Device related sepsisInfections and infestations | 1/60 |
| Septic shockInfections and infestations | 1/60 |
| Dengue feverInfections and infestations | 1/60 |
| Urinary tract infectionInfections and infestations | 1/60 |
| Viral infectionInfections and infestations | 1/60 |
| Serum sickness-like reactionImmune system disorders | 1/60 |
| Anaphylactic reactionImmune system disorders | 1/60 |
| TachycardiaCardiac disorders | 1/60 |
| Event | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| PyrexiaGeneral disorders | 11/60 |
| Peripheral sensory neuropathyNervous system disorders | 7/60 |
| NeutropeniaBlood and lymphatic system disorders | 6/60 |
| DiarrhoeaGastrointestinal disorders | 6/60 |
| Neuropathy peripheralNervous system disorders | 6/60 |
| AnaemiaBlood and lymphatic system disorders | 5/60 |
| NauseaGastrointestinal disorders | 5/60 |
| Upper respiratory tract infectionInfections and infestations | 5/60 |
| PolyneuropathyNervous system disorders | 5/60 |
| VomitingGastrointestinal disorders | 4/60 |
Safety Population included all enrolled participants who received at least 1 dose of brentuximab vedotin.
| Age, Continuous(years) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 35.4 ± 13.83 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Female | 24 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 58 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 18 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 42 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Czech Republic | 3 |
| Germany | 2 |
| Malaysia | 8 |
| Poland | 26 |
| Spain | 2 |
| Thailand | 10 |
| Turkey | 9 |
| Baseline Height(cm) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 171.0 ± 9.66 |
| Baseline Weight(kg) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 70.3 ± 19.41 |
| Body Mass Index (BMI)(kg/m^2) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Mean | 23.864 ± 5.4085 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2014 to primary completion in Mar 2016, 24 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Millennium Pharmaceuticals, Inc. →